Table 1.
Baseline patient demographics and baseline characteristics depending on CAT response at V5/LOCF
| Baseline demographics and characteristicsa | CAT responder Yes (N = 329) | CAT responder No (N = 288) | |
|---|---|---|---|
| Sex | Male, n (%) | 179 (54.4) | 160 (55.6) |
| Female, n (%) | 150 (45.6) | 128 (44.4) | |
| Age (year), mean ± SD | 66.7 ± 9.8 | 66.7 ± 9.5 | |
| BMI (kg/m2), mean ± SD | 27.4 ± 5.6 | 26.8 ± 5.4 | |
| Smoking status | Active smoker, n (%) | 121 (36.8) | 111 (38.5) |
| Former smoker, n (%) | 163 (49.5) | 152 (52.8) | |
| Non-smoker, n (%) | 45 (13.7) | 25 (8.7) | |
| Atopic patient, n (%) | 31 (9.4) | 17 (5.9) | |
| Asthma diagnosis before 40th year of age, n (%) | 36 (10.9) | 17 (5.9) | |
| Chronic bronchitis at first diagnosis, n (%) | 154 (47.0) | 137 (47.7) | |
| GOLD spirometry grade | GOLD II, n (%) | 195 (59.3)* | 142 (49.5) |
| GOLD III, n (%) | 134 (40.7)* | 145 (50.5) | |
| Rate of COPD exacerbations in the prior 12 months | Total, mean ± SD | 1.4 ± 0.7 | 1.4 ± 0.8 |
| Mild, mean ± SD | 0.4 ± 0.7 | 0.4 ± 0.8 | |
| Moderate, mean ± SD | 0.9 ± 0.8 | 0.8 ± 0.8 | |
| Severe, mean ± SD | 0.1 ± 0.3 | 0.1 ± 0.4 | |
| Total CAT score, mean ± SD | 23.0 ± 6.5** | 19.7 ± 6.1 | |
| FEV1 (L), mean ± SD | 1.446 ± 0.491 | 1.422 ± 0.504 | |
| mMRC grading | Grade 0-I, n (%) | 93 (28.6) | 72 (25.0) |
| Grade II-IV, n (%) | 233 (71.5) | 216 (74.9) | |
| Peripheral blood eosinophil count (%), mean ± SD# | 3.1 ± 2.8 | 2.7 ± 1.7 | |
| Peripheral blood eosinophils (cells/µl), mean ± SD## | 243.0 ± 225.1 | 212.9 ± 149.5 | |
| Prior treatment | LAMA/LABA/ICSb, n (%) | 77 (23.4) | 82 (28.5) |
| ICS/LABAb, n (%) | 60 (18.2) | 45 (15.6) | |
| LAMA/LABAb, n (%) | 192 (58.4) | 161 (55.9) | |
Group comparison p value (χ2-test or t test) *p < 0.05; **p < 0.0001, #N = 120; ## N = 115
BMI body mass index, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, GOLD Global initiative of chronic obstructive pulmonary disease, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic receptor antagonist, mMRC modified Medical Research Council Dyspnea Scale, SD standard deviation
aNumber of missing values varied between the described patient demographics and characteristics
bFixed or free combination